Outlook Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. 

CEO
Robert Charles Jahr
CEORobert Charles Jahr
Employees
23
Employees23
Headquarters
Iselin, New Jersey
HeadquartersIselin, New Jersey
Founded
2010
Founded2010
Employees
23
Employees23

OTLK Key Statistics

Market cap
93.21M
Market cap93.21M
Price-Earnings ratio
-1.61
Price-Earnings ratio-1.61
Dividend yield
—
Dividend yield—
Average volume
1.01M
Average volume1.01M
High today
$2.37
High today$2.37
Low today
$2.13
Low today$2.13
Open price
$2.36
Open price$2.36
Volume
861.08K
Volume861.08K
52 Week high
$9.10
52 Week high$9.10
52 Week low
$0.87
52 Week low$0.87

People also own

Based on the portfolios of people who own OTLK. This list is generated using Robinhood data, and it’s not a recommendation.
SNDL
Ocugen, Inc
NIO
Cenntro Inc.
Tilray Brands
Plug Power
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.